TY - JOUR
KW - Database
KW - diabetes mellitus, type 2
KW - Electronic Health Records
KW - Glomerular Filtration Rate
KW - metformin
KW - renal insufficiency, chronic
KW - Retrospective Studies
AU - C. Pollock
AU - J. Sanchez
AU - J. Carrero
AU - S. Kumar
AU - R. Pecoits-Filho
AU - C. Lam
AU - H. Chen
AU - E. Kanda
AU - M. Lainscak
AU - D. Wheeler
AD - Royal North Shore Hospital, Kolling Institute, University of Sydney, St Leonards, New South Wales, Australia.
Global Market Access and Pricing, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Real World Data Science, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, USA.
School of Medicine, Pontifical Catholic University of Parana, Curitiba, Brazil.
Arbor Research Collaborative for Health, Ann Arbor, Michigan, USA.
Department of Cardiology, National Heart Centre Singapore, Singapore City, Singapore.
Duke-NUS Medical School, Singapore City, Singapore.
Medical and Payer Evidence Statistics, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, USA.
Kawasaki Medical School, Kurashiki, Japan.
Division of Cardiology, General Hospital Murska Sobota, and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Department of Renal Medicine, University College London, London, UK.
AN - 37578188
BT - Diabet Med
DO - 10.1111/dme.15200
DP - NLM
ET - 2023/08/14
LA - eng
N1 - 1464-5491
Pollock, Carol
Sanchez, Juan Jose Garcia
Carrero, Juan-Jesus
Kumar, Supriya
Pecoits-Filho, Roberto
Lam, Carolyn S P
Chen, Hungta
Kanda, Eiichiro
Lainscak, Mitja
Wheeler, David C
Orcid: 0000-0003-0745-3478
AstraZeneca/
Journal Article
England
Diabet Med. 2023 Aug 14:e15200. doi: 10.1111/dme.15200.
PY - 2023
SN - 0742-3071
EP - e15200
T2 - Diabet Med
TI - Glucose-lowering treatment pathways of individuals with chronic kidney disease and type 2 diabetes according to the Kidney Disease: Improving Global Outcomes 2012 risk classification
ER -